Through a new agreement, Melinta Therapeutics has acquired the infectious disease business from The Medicines Company.  The deal includes the sale of global rights and all business supporting Vabomere, Orbactiv, and Minocin IV.    Recently launched and FDA approved Vabomere is a novel fixed-dose combination agent comprising of vaborbactam, a beta-lactamase inhibitor, and meropenem. Orbactiv is an injectable product approved by the FDA and EMA for the treatment of adults with acute bacter...